Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).

NCT00430365 is registered in ClinicalTrials.gov with University Hospital, Toulouse as lead sponsor.

NCT NCT00430365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00430365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).
Lead sponsor
University Hospital, Toulouse
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
September 30, 2018
Enrollment
614 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

myeloma